Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allakos Inc (NQ: ALLK )

1.255 +0.005 (+0.40%)
Streaming Delayed Price Updated: 10:58 AM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allakos Inc

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
From Allakos Inc.
Via GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Allakos Announces a Restructuring to Focus on Development of AK006
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Appoints Neil Graham to its Board of Directors
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
From Allakos Inc.
Via GlobeNewswire
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
From Allakos Inc.
Via GlobeNewswire
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
From Allakos Inc.
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.